ライフサイエンスコーパス: antibody-dependent enhancement

1 nd vice versa because of a phenomenon termed antibody-dependent enhancement.

2 erity of secondary flavivirus infections via antibody-dependent enhancement.

3 severe disease through a mechanism known as antibody-dependent enhancement.

4 her likelihood of serious disease because of antibody-dependent enhancement.

5 s development stages and sensitively detects antibody-dependent enhancement, a critical safety consid

6 ve broad HA reactivity, yet they do not have antibody-dependent enhancement activity.

7 lusion, here we find that in the presence of Antibody Dependent Enhancement (ADE) heterogeneity can i

8 We first consider antibody dependent enhancement (ADE) in which antibody e

9 Crosslinking of Fc with FcgammaRIIB mediates antibody-dependent enhancement (ADE) activity by MW05.

10 evere dengue disease focus on the process of antibody-dependent enhancement (ADE) as a primary risk f

11 p-regulated DENV infection by a mechanism of antibody-dependent enhancement (ADE) in a variety of Fc

12 investigates the complex dynamics induced by antibody-dependent enhancement (ADE) in multiserotype di

13 Antibody-dependent enhancement (ADE) is a mechanism by w

14 Antibody-dependent enhancement (ADE) is implicated in se

15 sed severity seen in secondary infections is antibody-dependent enhancement (ADE) leading to increase

16 The proposed antibody-dependent enhancement (ADE) mechanism for sever

17 uses, which may aggravate the disease via an antibody-dependent enhancement (ADE) mechanism.

18 tate Zika virus (ZIKV) infection through the antibody-dependent enhancement (ADE) mechanism.

19 Th1-biased response in mice, and there is no antibody-dependent enhancement (ADE) observed.

20 Antibody-dependent enhancement (ADE) of dengue virus (DE

21 ucidate the mechanisms of neutralization and antibody-dependent enhancement (ADE) of DENV infections,

22 protection against DENV disease and prevents antibody-dependent enhancement (ADE) of disease in mice.

23 Antibody-dependent enhancement (ADE) of disease is a gen

24 h as dengue virus, exhibit the phenomenon of antibody-dependent enhancement (ADE) of disease, making

25 rns for cross-reactive responses that induce antibody-dependent enhancement (ADE) of heterologous fla

26 knowledge of the functional requirements of antibody-dependent enhancement (ADE) of infection beyond

27 Fc gamma receptors (FcgR)-a process known as antibody-dependent enhancement (ADE) of infection.

28 oorly neutralizing antibodies that can cause antibody-dependent enhancement (ADE) of infection.

29 Antibody-dependent enhancement (ADE) of viral entry has

30 cination and antiviral strategies.IMPORTANCE Antibody-dependent enhancement (ADE) of viral entry has

31 rate the capability of this system to detect antibody-dependent enhancement (ADE) of virus entry as a

32 mmune serum, it has been shown in vitro that antibody-dependent enhancement (ADE) of ZIKV infection c

33 ble of both cross-neutralization, as well as antibody-dependent enhancement (ADE) of ZIKV infection.

34 cross-reaction to ZIKV and was able to drive antibody-dependent enhancement (ADE) of ZIKV infection.

35 te disease caused by related viruses through antibody-dependent enhancement (ADE) or interfere with t

36 Moreover, antibody-dependent enhancement (ADE) was not observed ag

37 infection of myeloid cells-a process termed antibody-dependent enhancement (ADE)(1,4,5).

38 Antibody-dependent enhancement (ADE), a phenomenon in wh

39 Antibody-dependent enhancement (ADE), a process best des

40 e virus (DENV) infections is associated with antibody-dependent enhancement (ADE), and it was recentl

41 This burden is commonly attributed to antibody-dependent enhancement (ADE), whereby concentrat

42 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE).

43 This phenomenon is referred to as antibody-dependent enhancement (ADE).

44 eutralization potency, enhanced infection by antibody-dependent enhancement (ADE).

45 tope antibodies that are known to facilitate antibody-dependent enhancement (ADE).

46 e-infection, mainly because of the effect of antibody-dependent enhancement (ADE).

47 -glycoprotein (g)D and anti-gK antibodies on antibody-dependent enhancement (ADE).

48 tate infection through a phenomenon known as antibody-dependent enhancement (ADE).

49 SARS-CoV-2, including somatic mutations and antibody-dependent enhancement (ADE).

50 ersistent infection, by Fc-receptor-mediated antibody-dependent enhancement (ADE).

51 o an alternative route of viral entry termed antibody-dependent enhancement (ADE).

52 s from all four serotypes to avoid potential antibody-dependent enhancement (ADE).

53 dengue can enhance subsequent infections via antibody-dependent enhancement (ADE).

54 eved to contribute to severe disease through antibody-dependent enhancement (ADE).

55 creased infectivity of susceptible cells via antibody-dependent enhancement (ADE).

56 Progression to DHF/DSS is attributed to antibody-dependent enhancement (ADE); however, because o

57 tions in flavivirus immune vaccinees such as Antibody-Dependent Enhancement (ADE, a phenomenon involv

58 DENV infection was enhanced (through antibody-dependent enhancement [ADE]) or was suppressed

59 ur mostly during secondary infections due to antibody-dependent enhancement after infection with a di

60 kly neutralizing they also may contribute to antibody-dependent enhancement and flavi virus pathogene

61 unopathology is thought to play a part, with antibody-dependent enhancement and massive immune activa

62 l antibody, engineered to reduce the risk of antibody-dependent enhancement and prolong half-life, ne

63 adly neutralizing antibodies with no risk of antibody-dependent enhancement are required for the trea

64 ines identified cellular immunopathology and antibody-dependent enhancement as potential safety issue

65 nteractions, arising from cross-immunity and antibody-dependent enhancement, between related pathogen

66 ovide statistical support for the process of antibody-dependent enhancement (but not original antigen

67 Complement-mediated, antibody-dependent enhancement (C'-ADE) of HIV-1IIIB and

68 Antibody-dependent enhancement has been implicated in mo

69 For decades antibody-dependent enhancement has been the prevalent mo

70 , and provides evidence for the mechanism of antibody-dependent enhancement in dengue cases.

71 ZIKV co-circulate, understanding the role of antibody-dependent enhancement in the context of pregnan

72 human sera (PHS) and the major mediators of antibody-dependent enhancement in the presence of PHS.

73 Antibody-dependent enhancement is linked to antibodies t

74 Among the 4 serotypes of dengue virus, antibody-dependent enhancement is thought to enhance vir

75 Antibody-dependent enhancement may explain the severe di

76 ion showed significant capacity for in vitro antibody dependent enhancement of Dengue-1, 2, 3 and 4 s

77 In contrast, antibody-dependent enhancement of bacterial infection is

78 depletion, autoimmune hemolytic anemia, and antibody-dependent enhancement of dengue disease, reveal

79 While antibody-dependent enhancement of dengue is thought to b

80 I agonist blocked both primary infection and antibody-dependent enhancement of DENV infection.

81 -gamma receptor (FcgammaR), a process termed antibody-dependent enhancement of DENV infection.

82 on in the Fc region which completely ablates antibody-dependent enhancement of DENV replication in vi

83 lobulins specific for Zika virus that lacked antibody-dependent enhancement of disease, and hyperimmu

84 , indicating their possible ability to cause antibody-dependent enhancement of disease.

85 mune effector functions but could potentiate antibody-dependent enhancement of disease.

86 f targeted therapeutic approaches to prevent antibody-dependent enhancement of disease.

87 nsfer of intact anti-prM mAbs resulted in an antibody-dependent enhancement of disease.

88 ted against DENV-2 by using a mouse model of antibody-dependent enhancement of infection (ADE)-induce

89 ary mode of infection used by ImmZIKV is via antibody-dependent enhancement of infection (ADE)-the fo

90 This process has been termed antibody-dependent enhancement of infection and has sign

91 zed all four serotypes of DENV, and mediated antibody-dependent enhancement of infection in Fc recept

92 ucleoside-modified mRNA vaccines do not show antibody-dependent enhancement of infection in vitro.

93 ation and clearance are facilitated, whereas antibody-dependent enhancement of infection is inhibited

94 One possibility is that ZIKV may exploit the antibody-dependent enhancement of infection mechanism, m

95 ) abrogated FcyR engagement, reduced risk of antibody-dependent enhancement of infection, and reduced

96 mRNA vaccines, including one that minimizes antibody-dependent enhancement of infection, elicited hi

97 pite many advances indicating a key role for antibody-dependent enhancement of infection.

98 Antibody-dependent enhancement of infectivity was observ

99 These results suggest that antibody-dependent enhancement of NK activity may yield

100 n in late infancy is a direct consequence of antibody-dependent enhancement of replication.

101 Although suspected, such antibody-dependent enhancement of severe disease has not

102 raction of FcgammaRI with A1H3 underlays the antibody-dependent enhancement of the cellular effects o

103 antibody and show that this antibody causes antibody-dependent enhancement of toxicity (ADET) of myo

104 rceived wisdom, patterns generated solely by antibody-dependent enhancement or heterogeneity in virus

105 Antibody-dependent enhancement was observed in animals i

106 rus (DENV) pathogenesis is the potential for antibody-dependent enhancement, which is associated with

107 re weakly neutralizing and frequently induce antibody-dependent enhancement, which promotes viral ent